These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35439535)

  • 1. Pan-mTOR inhibitors sensitize the senolytic activity of navitoclax via mTORC2 inhibition-mediated apoptotic signaling.
    Xu W; Zhao T; Chen H; Huang N; Gong H; Zhang J; Yang Y; Li T; Zhang G; Gong C; Yang M; Xiao H
    Biochem Pharmacol; 2022 Jun; 200():115045. PubMed ID: 35439535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with the BCL-2/BCL-xL inhibitor senolytic drug ABT263/Navitoclax improves functional hyperemia in aged mice.
    Tarantini S; Balasubramanian P; Delfavero J; Csipo T; Yabluchanskiy A; Kiss T; Nyúl-Tóth Á; Mukli P; Toth P; Ahire C; Ungvari A; Benyo Z; Csiszar A; Ungvari Z
    Geroscience; 2021 Oct; 43(5):2427-2440. PubMed ID: 34427858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells.
    Escriche-Navarro B; Garrido E; Sancenón F; García-Fernández A; Martínez-Máñez R
    Acta Biomater; 2024 Mar; 176():405-416. PubMed ID: 38185231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.
    Zhu Y; Tchkonia T; Fuhrmann-Stroissnigg H; Dai HM; Ling YY; Stout MB; Pirtskhalava T; Giorgadze N; Johnson KO; Giles CB; Wren JD; Niedernhofer LJ; Robbins PD; Kirkland JL
    Aging Cell; 2016 Jun; 15(3):428-35. PubMed ID: 26711051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity.
    González-Gualda E; Pàez-Ribes M; Lozano-Torres B; Macias D; Wilson JR; González-López C; Ou HL; Mirón-Barroso S; Zhang Z; Lérida-Viso A; Blandez JF; Bernardos A; Sancenón F; Rovira M; Fruk L; Martins CP; Serrano M; Doherty GJ; Martínez-Máñez R; Muñoz-Espín D
    Aging Cell; 2020 Apr; 19(4):e13142. PubMed ID: 32233024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EA.hy926 Cells and HUVECs Share Similar Senescence Phenotypes but Respond Differently to the Senolytic Drug ABT-263.
    Abdelgawad IY; Agostinucci K; Ismail SG; Grant MKO; Zordoky BN
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents that target senescent cells: the flavone, fisetin, and the BCL-X
    Zhu Y; Doornebal EJ; Pirtskhalava T; Giorgadze N; Wentworth M; Fuhrmann-Stroissnigg H; Niedernhofer LJ; Robbins PD; Tchkonia T; Kirkland JL
    Aging (Albany NY); 2017 Mar; 9(3):955-963. PubMed ID: 28273655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs.
    Bogdanova DA; Kolosova ED; Pukhalskaia TV; Levchuk KA; Demidov ON; Belotserkovskaya EV
    Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mTORC1/2 Inhibitor AZD8055 Strengthens the Efficiency of the MEK Inhibitor Trametinib to Reduce the Mcl-1/[Bim and Puma] ratio and to Sensitize Ovarian Carcinoma Cells to ABT-737.
    Pétigny-Lechartier C; Duboc C; Jebahi A; Louis MH; Abeilard E; Denoyelle C; Gauduchon P; Poulain L; Villedieu M
    Mol Cancer Ther; 2017 Jan; 16(1):102-115. PubMed ID: 27980105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice.
    Fielder E; Wan T; Alimohammadiha G; Ishaq A; Low E; Weigand BM; Kelly G; Parker C; Griffin B; Jurk D; Korolchuk VI; von Zglinicki T; Miwa S
    Elife; 2022 May; 11():. PubMed ID: 35507395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pan-mammalian target of rapamycin (mTOR) inhibitor AZD8055 primes rhabdomyosarcoma cells for ABT-737-induced apoptosis by down-regulating Mcl-1 protein.
    Preuss E; Hugle M; Reimann R; Schlecht M; Fulda S
    J Biol Chem; 2013 Dec; 288(49):35287-96. PubMed ID: 24133218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma.
    Wang Q; Wei F; Li C; Lv G; Wang G; Liu T; Bellail AC; Hao C
    PLoS One; 2013; 8(8):e73175. PubMed ID: 23991179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of radiation-induced micronuclei associated with premature senescence, and their selective removal by senolytic drug, ABT-263.
    Suzuki K; Kawamura K; Ujiie R; Nakayama T; Mitsutake N
    Mutat Res Genet Toxicol Environ Mutagen; 2022; 876-877():503448. PubMed ID: 35483779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor PF-04691502 works as a senolytic to regulate cellular senescence.
    Fan Z; Tong Y; Yang Z; Wang S; Huang T; Yang D; Ni Q; Zhang M; Li D; Yang M; Fan X
    Exp Gerontol; 2024 Feb; 186():112359. PubMed ID: 38184267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of SYK inhibitor, R406 as a novel senolytic agent.
    Cho HJ; Yang EJ; Park JT; Kim JR; Kim EC; Jung KJ; Park SC; Lee YS
    Aging (Albany NY); 2020 May; 12(9):8221-8240. PubMed ID: 32379705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
    Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
    Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined inhibition of class 1-PI3K-alpha and delta isoforms causes senolysis by inducing p21
    Neuwahl J; Neumann CA; Fitz AC; Biermann AD; Magel M; Friedrich A; Sellin L; Stork B; Piekorz RP; Proksch P; Budach W; Jänicke RU; Sohn D
    Cell Death Dis; 2024 May; 15(5):373. PubMed ID: 38811535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing spontaneous cerebral microhemorrhages in aging mice: a novel approach targeting cellular senescence with ABT263/navitoclax.
    Faakye J; Nyúl-Tóth Á; Muranyi M; Gulej R; Csik B; Shanmugarama S; Tarantini S; Negri S; Prodan C; Mukli P; Yabluchanskiy A; Conley S; Toth P; Csiszar A; Ungvari Z
    Geroscience; 2024 Feb; 46(1):21-37. PubMed ID: 38044400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Senescence-Independent Anti-Inflammatory Activity of the Senolytic Drugs Dasatinib, Navitoclax, and Venetoclax in Zebrafish Models of Chronic Inflammation.
    Hernández-Silva D; Cantón-Sandoval J; Martínez-Navarro FJ; Pérez-Sánchez H; de Oliveira S; Mulero V; Alcaraz-Pérez F; Cayuela ML
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the HDAC/PI3K inhibitor CUDC-907 as a novel senolytic.
    Al-Mansour F; Alraddadi A; He B; Saleh A; Poblocka M; Alzahrani W; Cowley S; Macip S
    Aging (Albany NY); 2023 Mar; 15(7):2373-2394. PubMed ID: 36988504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.